Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 May 31;13(5):884-888.
doi: 10.21037/tau-23-671. Epub 2024 May 17.

Rucaparib monotherapy in the heavily pre-treated metastatic castrate-resistant prostate cancer setting: practical considerations and alternate treatment approaches

Rashid K Sayyid  1 , Rui Bernardino  1 , Julian Chavarriaga  1 , Alexandra Gleave  2 , Ravi Kumar  1 , Neil E Fleshner  1
Affiliations
Editorial

Rucaparib monotherapy in the heavily pre-treated metastatic castrate-resistant prostate cancer setting: practical considerations and alternate treatment approaches

Rashid K Sayyid et al. Transl Androl Urol. .
No abstract available

Keywords: Prostatic neoplasms; castration; chemotherapy; poly(ADP-ribose) polymerase inhibitors (PARPi).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tau.amegroups.com/article/view/10.21037/tau-23-671/coif). Neil E. Fleshner reports grants and personal fees from Janssen, Astellas, Bayer, and Sanofi; grants from Nucleix, Progenix, and the Ontario Institute for Cancer Research; and personal fees from Amgen, Abbvie, Ferring, Verity Pharmaceuticals, and POINTBiopharma outside the submitted work. The other authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Current United States FDA-approved drugs in the metastatic castrate-resistant prostate cancer space. *, progressed following androgen-axis targeted treatment and taxane-based chemotherapy; **, progressed following treatment with enzalutamide or abiraterone. dMMR, DNA mismatch repair deficiency; MSI-H, microsatellite instability high; BRCA, BReast CAncer; HRR, homologous recombination repair; FDA, Food and Drug Administration; mCRPC, metastatic castrate-resistant prostate cancer.
See this image and copyright information in PMC

Comment on

References

    1. FDA grants accelerated approval to rucaparib for BRCA-mutated metastatic castration-resistant prostate cancer. Available online: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grant... (accessed on October 9, 2023).
    1. Abida W, Patnaik A, Campbell D, et al. Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration. J Clin Oncol 2020;38:3763-72. 10.1200/JCO.20.01035 - DOI - PMC - PubMed
    1. FDA approves olaparib for HRR gene-mutated metastatic castration-resistant prostate cancer. Available online: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-appro... (accessed on October 9, 2023).
    1. de Bono J, Mateo J, Fizazi K, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med 2020;382:2091-102. 10.1056/NEJMoa1911440 - DOI - PubMed
    1. FDA D.I.S.C.O. Burst Edition: FDA approval of Lynparza (olaparib), with abiraterone and prednisone, for BRCA-mutated metastatic castration-resistant prostate cancer. Available online: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco... (accessed on October 9, 2023).